» Articles » PMID: 30601864

Safety, Health Improvement and Well-being During a 4 to 21-day Fasting Period in an Observational Study Including 1422 Subjects

Overview
Journal PLoS One
Date 2019 Jan 3
PMID 30601864
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

Only few studies document longer periods of fasting in large cohorts including non-obese participants. The aim of this study was to document prospectively the safety and any changes in basic health and well-being indicators during Buchinger periodic fasting within a specialised clinic. In a one-year observational study 1422 subjects participated in a fasting program consisting of fasting periods of between 4 and 21 days. Subjects were grouped in fasting period lengths of 5, 10, 15 and 20±2 days. The participants fasted according to the Buchinger guidelines with a daily caloric intake of 200-250 kcal accompanied by a moderate-intensity lifestyle program. Clinical parameters as well as adverse effects and well-being were documented daily. Blood examinations before and at the end of the fasting period complemented the pre-post analysis using mixed-effects linear models. Significant reductions in weight, abdominal circumference and blood pressure were observed in the whole group (each p<0.001). A beneficial modulating effect of fasting on blood lipids, glucoregulation and further general health-related blood parameters was shown. In all groups, fasting led to a decrease in blood glucose levels to low norm range and to an increase in ketone bodies levels (each p<0.001), documenting the metabolic switch. An increase in physical and emotional well-being (each p<0.001) and an absence of hunger feeling in 93.2% of the subjects supported the feasibility of prolonged fasting. Among the 404 subjects with pre-existing health-complaints, 341 (84.4%) reported an improvement. Adverse effects were reported in less than 1% of the participants. The results from 1422 subjects showed for the first time that Buchinger periodic fasting lasting from 4 to 21 days is safe and well tolerated. It led to enhancement of emotional and physical well-being and improvements in relevant cardiovascular and general risk factors, as well as subjective health complaints.

Citing Articles

Prophylactic effects of nutrition, dietary strategies, exercise, lifestyle and environment on nonalcoholic fatty liver disease.

Hao X, Song H, Su X, Li J, Ye Y, Wang C Ann Med. 2025; 57(1):2464223.

PMID: 39943720 PMC: 11827040. DOI: 10.1080/07853890.2025.2464223.


Dietary Restrictions and Cancer Prevention: State of the Art.

Caprara G, Pallavi R, Sanyal S, Pelicci P Nutrients. 2025; 17(3).

PMID: 39940361 PMC: 11820753. DOI: 10.3390/nu17030503.


Investigating the Impact of Glycogen-Depleting Exercise Combined with Prolonged Fasting on Autophagy and Cellular Health in Humans: A Randomised Controlled Crossover Trial.

Masedunskas A, de Ciutiis I, Hein L, Ge A, Kong Y, Qi M Nutrients. 2025; 16(24.

PMID: 39770918 PMC: 11677747. DOI: 10.3390/nu16244297.


Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.

Duraj T, Kalamian M, Zuccoli G, Maroon J, DAgostino D, Scheck A BMC Med. 2024; 22(1):578.

PMID: 39639257 PMC: 11622503. DOI: 10.1186/s12916-024-03775-4.


Analysis of physiological and biochemical changes and metabolic shifts during 21-Day fasting hypometabolism.

Dai Z, Zhang H, Sui X, Wu F, Zhang C, Fan Z Sci Rep. 2024; 14(1):28550.

PMID: 39557965 PMC: 11574170. DOI: 10.1038/s41598-024-80049-2.


References
1.
Yamada Y, Kemnitz J, Weindruch R, Anderson R, Schoeller D, Colman R . Caloric Restriction and Healthy Life Span: Frail Phenotype of Nonhuman Primates in the Wisconsin National Primate Research Center Caloric Restriction Study. J Gerontol A Biol Sci Med Sci. 2017; 73(3):273-278. PMC: 5861888. DOI: 10.1093/gerona/glx059. View

2.
Becker B . Towards the physiological function of uric acid. Free Radic Biol Med. 1993; 14(6):615-31. DOI: 10.1016/0891-5849(93)90143-i. View

3.
THOMSON T, Runcie J, Miller V . Treatment of obesity by total fasting for up to 249 days. Lancet. 1966; 2(7471):992-6. DOI: 10.1016/s0140-6736(66)92925-4. View

4.
Mattson M, Moehl K, Ghena N, Schmaedick M, Cheng A . Intermittent metabolic switching, neuroplasticity and brain health. Nat Rev Neurosci. 2018; 19(2):63-80. PMC: 5913738. DOI: 10.1038/nrn.2017.156. View

5.
Ruscica M, Ferri N, Macchi C, Corsini A, Sirtori C . Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. Ann Med. 2018; 50(6):461-484. DOI: 10.1080/07853890.2018.1498118. View